Foreign firms may be re-calibrating their India market strategy but wider concerns of their waning interest in the ultra-competitive and largely out-of-pocket market may be unfounded, at least for now.
Foreign Firms Not Fatigued In India, Game For 'New Things'
Senior management executives of Roche, Bayer, AstraZeneca, Pfizer and Novo Nordisk in India signal momentum in product launch and clinical trial activity, belying apprehension of wider cutbacks by foreign firms in the country, though one executive stressed that “tried and tested models” may not work in the largely self-pay market.
More from Business
• By
Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.
• By
Public Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.
• By
On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.